Access Biotechnology led Hemab Therapeutics’ $135m series B round while South Africa's Sasol launched a $53m CVC partnership with Emerald Technology Ventures.
Funds
South African chemicals and energy group Sasol formed a €50m ($53.3m) corporate venturing arm dubbed Sasol Ventures that will be managed by Switzerland-headquartered venture capital firm Emerald Technology Ventures as investment adviser. Sasol Ventures will target sustainable chemicals and energy technologies that can decarbonise its operations.
Japan-based venture capital firm Animal Spirits has secured limited partners including taxi and limousine operator Nihon Kotsu and leasing…
